Summit, NJ-Based Celgene, Like Many Multi-National Drug Companies, Reported a 4Q 2017 Earnings Charge Due to the Impact of the Trump Tax Bill. In Celgene's Case, This 4Q 2017 Earnings Charge Amounted to $1.269 Bil.